

TREATMENT OF CENTRAL NERVOUS SYSTEM
DISEASES BY ANTIBODIES AGAINST GLATIRAMER ACETATE

Abstract of the Disclosure

5 The present invention provides humanized polyclonal and
humanized monoclonal antibodies directed against an epitope
on glatiramer acetate, also known as Copolymer 1, Copolymer-
1, Cop-1 or Cop. Additionally, the subject invention
concerns a pharmaceutical composition comprising an antibody
10 directed against an epitope on glatiramer acetate for the
treatment of a disease associated with demyelination of
central nervous system axons. Also encompassed by the
subject invention is a method of treating a subject suffering
from a disease associated with demyelination of central
15 nervous system axons. The subject invention further contains
methods of stimulating remyelination of central nervous
system axons. In addition, the subject invention provides a
method of stimulating proliferation of lymphocytes.